Estonian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Uric Acid Effects on Endothelium and Oxydative Stress

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Link salvestatakse lõikelauale
StaatusValmis
Sponsorid
Erasme University Hospital
Kaastöötajad
Fonds Erasme
Fonds National de la Recherche Scientifique

Märksõnad

Abstraktne

Cardiovascular disease is the leading cause of mortality worldwide. Endothelial dysfunction (ED) is the main mechanism which leads to atherosclerosis, where the balance between pro and antioxidant factors results in a decreased nitric oxide (NO) bioavailability. Xanthine OxidoReductase (XOR) is one of the main generators of reactive oxygen species (ROS). Uric acid (UA), a major antioxidant in human plasma and end product of purine metabolism, is associated with cardiovascular diseases since many years; however the precise mechanisms which relate UA to ED are still not well understood.
The purpose of this study is to unravel the XOR and UA pathways involved in ED. Three groups of participants (young (< 40 y) male healthy participants [1] ; male and female helthy participants (40 to 65 y) [2] and patients with primary hypertension [3]) will be exposed to febuxostat (a strong and selective XOR inhibitor), or recombinant uricase (which oxidizes UA into allantoin) to vary UA levels and concomitantly control for confounding changes in XOR activity. Oxidative stress will be estimated by several markers. Endothelial function will be assessed by a laser Doppler imager in the presence of hyperthermia and endothelium stimulators. This study is specifically designed to untie the respective effects of UA and XOR pathways on oxidative stress and endothelial function in humans.
The investigators will test the following hypothesis:
1. An extremely low level of uric acid after uricase administration induces endothelial dysfunction and oxydative stress,
2. A specific XO inhibitor limits unfavourable effects of the serum UA reduction elicited by uricase administration,
3. Endothelial function and oxydative stress are further improved with febuxostat as compared to placebo,
4. All these observations are more marked in hypertensives then in older participants than in young healthy subjects.

Kirjeldus

The goals of the research protocol are to clearly untie the respective roles of uric acid (UA) and xanthine oxidoreductase (XOR) pathways on endothelial function and oxidative stress in humans.

UA represents the end-product of purine metabolism due to the loss of uricase 15 million years ago in humans. The selective advantage of this mutation could be the strong antioxidant effect of UA (which represents more than 60% of the antioxidant plasmatic capacity). Many recent epidemiological studies have showed a J-shape association between UA levels and cardiovascular risk. An UA level lower than 3 mg/dl could be damageable due to the loss of the antioxidant properties of UA. In contrast, hyperuricemia is associated with an increased inflammation, insulin resistance, ED, platelet aggregation, left ventricle hypertrophy, arterial vasodilatation impairment, aortic stiffness and intima-media thickness. However, the association between UA and cardiovascular disease remains controversial because whether UA is an independent risk factor for these illnesses is unclear.

Interventional studies:

Because the above-mentioned associations do not prove causation, several authors designed interventional studies with the purpose to modify UA levels and determine if this affected endothelial function and oxidative stress. The main limitation of these studies is that they were unable to untie the effects of the synthesis of UA, of UA itself and of the activity of XOR, on ROS production and endothelial function in humans.

This is because:

1. serum UA is a powerful plasmatic antioxidant,

2. but transformation of hypoxanthine to xanthine and xanthine to UA by XO generates intracellular ROS,

3. moreover, in endothelial cells, UA reduces NO bioavailability by many ways (L-arginine blockade and degradation, increased superoxide anion production, NOS inhibition, reduced NOS genes expression and direct NO scavenging),

4. in addition, UA forms crystals in the endothelium wall which create a pro-inflammatory and thrombotic state, increases smooth muscle cells proliferation and also insulin resistance and inflammation in adipocytes,

5. finally, and most importantly, XO is inhibited by physiologic levels of UA (which acts as an uncompetitive XO inhibitor).

In summary, the present protocol aims at testing the following hypothesis:

1. Experimental serum UA variations are correlated with endothelial function and oxydative stress markers : an extremely low level after uricase administration induces ED and oxydative stress,

2. A specific XO inhibitor (FX) limits unfavourable effects of the serum UA reduction elicited by uricase administration, since this will hamper the feedback activation of XO by a low UA level,

3. Endothelial function and oxydative stress are further improved with FX as compared to placebo, because the first experimental condition results in a XO blockade,

4. All these observations are more marked in hypertensive patients then in older participants than in young healthy subjects.

Data collection

Data collection from the participants will be collected informatically through a case report form. The names and personnal data from the patients will be kept in a secret place or in a password-protected file. All the data will be destroyed at the end of the study (including blood and urine samples).

Statistical analysis

Statistical analysis will be performed using SPSS. Baseline characteristics will be compared using a Student t test. Two-way repeated-measures ANOVAs will be used to detect significant changes between sessions and groups. Statistical significance is assumed when p is <0.05. Sample size is not possible due to the lack of data of the effect of acute hypouricemia. We estimate a minimum of 15 participants in each group.

Specific test will be used for non gaussian variables. Correlation test will be used if necessary according the results of the first test.

Placebo-corrected values and comparisons of the delta will be used too.

Subgroups analyses will be performed for the study of population 2 and 3 (enrolled together).

Kuupäevad

Viimati kinnitatud: 01/31/2020
Esmalt esitatud: 12/28/2017
Hinnanguline registreerumine on esitatud: 01/03/2018
Esmalt postitatud: 01/09/2018
Viimane värskendus on esitatud: 02/26/2020
Viimati värskendus postitatud: 02/27/2020
Õppe tegelik alguskuupäev: 01/02/2018
Eeldatav esmane lõpetamise kuupäev: 12/30/2019
Eeldatav uuringu lõpetamise kuupäev: 02/26/2020

Seisund või haigus

Oxidative Stress
Endothelial Function
Cardiovascular System
Hypertension

Sekkumine / ravi

Drug: Placebos

Drug: Febuxostat

Drug: Rasburicase

Faas

-

Käerühmad

ArmSekkumine / ravi
Placebo Comparator: Placebos PO and IV
PO : per os IV : intraveinously
Experimental: Febuxostat PO and Placebo IV
240 mg a day for 3 days
Experimental: Febuxostat PO And Rasburicase IV
Febuxostat : 240 mg a day for 3 days. Uricase : 3 mg once.
Experimental: Placebo PO And Rasburicase IV
Placebo : for 3 days. Uricase : 3 mg once.

Abikõlblikkuse kriteeriumid

Õppimiseks sobivad vanused 18 Years To 18 Years
Uuringuks kõlblikud soodAll
Võtab vastu tervislikke vabatahtlikkeJah
Kriteeriumid

Phase 1 :

Inclusion Criteria:

- Age between 18 and 40 years

- Male

- Healthy volunteers

- Non smoker for at least 6 months

- Uric acid level in normal range (normouricemic group)

Exclusion Criteria:

- Any diseases of one of the following systems: cardiovascular, digestive, hormonal, urinary, pulmonary, rheumatic or immune.

- Smoker, alcoholic

- Participants should not take any chronic medicine nor vitamins or other antioxidants.

- A G6PD deficit will be excluded as this is a contraindication to uricase administration (hemolytic anemia).

Phase 2 :

Inclusion Criteria:

- Age between 40 and 65 years

- Male or female (menopaused)

- Healthy volunteers

- Non smoker for at least 6 months

- Uric acid level in normal range (normouricemic group)

Exclusion Criteria:

- Any diseases of one of the following systems: cardiovascular, digestive, hormonal, urinary, pulmonary, rheumatic or immune.

- Smoker, alcoholic

- Participants should not take any chronic medicine nor vitamins or other antioxidants.

- A G6PD deficit will be excluded as this is a contraindication to uricase administration (hemolytic anemia).

Phase 3 :

Inclusion Criteria:

- Age between 40 and 65 years

- History of hypertension for more than 6 months

- Non smoker or smoke stopped for at least for 6 months

Exclusion Criteria:

- Acute coronary syndrome

- Heart failure (LVEJ < 40%)

- Diabetes

- Active smoking

- Gout

- Chronic kidney disease stage superior to 3a

- History of cerebrovascular thrombosis

- Cirrhosis

- Alcohol consumption more than 3 units/day

- Participants should not take any chronic medicine nor vitamins or other antioxidants.

- A G6PD deficit will be excluded as this is a contraindication to uricase administration (hemolytic anemia).

The populations of phases 2 and 3 will be enrolled and studied together with subgroups analyses of the results for the status of hypertension, of treatment, age and gender.

Tulemus

Esmased tulemusnäitajad

1. Cutaneous perfusion by Laser Doppler (perfusion unit) [24 hours after infusion of Uricase or Placebo]

Perfusion unit (Laser Doppler Imager + iontophoresis of (ACh and SNP and hyperemia with ou without L-NAME). Assessment of endothelial function.

Sekundaarsed tulemusmõõdud

1. Change in Oxydative stress biomarkers from baseline to 30 min or 24 hours after infusion of Uricase or Placebo [Baseline, 30 minutes and 24 hours after infusion of Uricase or Placebo]

2. Arterial stiffness [24 hours after infusion of Uricase or Placebo]

Carotido-femoral and carotido-radial pulse wave velocity and pulse wave analysis

3. Blood pressure (mmHg) [24 hours after infusion of Uricase or Placebo]

Beat-to-beat measurements with Finapres and manually

4. Cardiac output (l-min) [24 hours after infusion of Uricase or Placebo]

Beat-to-beat measurements with Finapres

5. Change in enzymes activity [30 min and 24 hours after infusion of Uricase or Placebo]

Xanthin oxydase activity

6. Change in enzymes expression [30 min and 24 hours after infusion of Uricase or Placebo]

eNOS, NOX, XO we will incubate endothelial cells with plasma or serum from subjects. Then we will measure the sus-mentionned enzymes' expression.

7. Change in proteomic or metabolomic analysis [30 min and 24 hours after infusion of Uricase or Placebo]

We will perform proteomics or metabolomics analysis directly on serum from participants and also on lysate of endothelial cells pre-incubated with plasma or serum from participants.

8. Change in renin-angiotensin activity [Baseline, 30 minutes and 24 hours after infusion of Uricase or Placebo]

9. Change in urinary excretion of sodium [Baseline, 30 minutes and 24 hours after infusion of Uricase or Placebo]

Liitu meie
facebooki lehega

Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus

  • Töötab 55 keeles
  • Taimsed ravimid, mida toetab teadus
  • Maitsetaimede äratundmine pildi järgi
  • Interaktiivne GPS-kaart - märgistage ürdid asukohas (varsti)
  • Lugege oma otsinguga seotud teaduspublikatsioone
  • Otsige ravimtaimi nende mõju järgi
  • Korraldage oma huvisid ja hoidke end kursis uudisteuuringute, kliiniliste uuringute ja patentidega

Sisestage sümptom või haigus ja lugege ravimtaimede kohta, mis võivad aidata, tippige ürdi ja vaadake haigusi ja sümptomeid, mille vastu seda kasutatakse.
* Kogu teave põhineb avaldatud teaduslikel uuringutel

Google Play badgeApp Store badge